PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2022 Financial Results

Rhea-AI Summary

PDS Biotechnology Corporation (Nasdaq: PDSB) will announce its third-quarter financial results on November 14, 2022, prior to market opening. A conference call will follow to discuss the results and provide a business update. The company focuses on developing immunotherapies targeting cancer and infectious diseases, utilizing its proprietary Versamune® and Infectimune™ technologies. The lead candidate, PDS0101, has shown promise in clinical trials for HPV-positive cancers.

FLORHAM PARK, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the Company will release financial results for the third quarter of 2022 on Monday, November 14, 2022, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update.

Monday, November 14, 2022, 8:00 AM EST
Domestic:		877-407-3088
International:		201-389-0927
Conference ID: 13733006
Webcast: PDS Biotech Earnings Webcast

After the live webcast, the event will be archived on PDS Biotech’s website for six months.

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune^® and Infectimune™ T cell-activating technology platforms. We believe our targeted Versamune^® based candidates have the potential to overcome the limitations of current immunotherapy by inducing large quantities of high-quality, potent polyfunctional tumor specific CD4+ helper and CD8+ killer T cells. To date, our lead Versamune^® clinical candidate, PDS0101, has demonstrated the potential to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV-positive cancers in multiple Phase 2 clinical trials. Our Infectimune™ based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Versamune^® is a registered trademark and Infectimune™ is a trademark of PDS Biotechnology.

Investor Contacts:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
drandolph@pdsbiotech.com

Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
pdsb@cg.capital

Media:
Dave Schemelia
Tiberend Strategic Advisors, Inc.
Phone: +1 (609) 468-9325
dschemelia@tiberend.com

Bill Borden
Tiberend Strategic Advisors, Inc.
Phone : +1 (732) 910-1620
bborden@tiberend.com

FAQ

When will PDSB release its third-quarter financial results?

PDSB will release its third-quarter financial results on November 14, 2022, before the market opens.

What is PDSB's lead immunotherapy candidate?

PDSB's lead immunotherapy candidate is PDS0101, which has shown potential in treating HPV-positive cancers.

What technologies does PDSB use for its immunotherapies?

PDSB uses its proprietary Versamune® and Infectimune™ technologies for developing its immunotherapies.

What time is the PDSB conference call scheduled?

The conference call is scheduled for November 14, 2022, at 8:00 AM EST.